PMC:7781431 / 10295-11306
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
313 | 199-204 | Gene | denotes | COX-2 | Gene:5743 |
314 | 366-371 | Gene | denotes | ALOX5 | Gene:240 |
315 | 20-25 | Gene | denotes | COX-2 | Gene:5743 |
316 | 3-8 | Species | denotes | human | Tax:9606 |
317 | 313-318 | Species | denotes | human | Tax:9606 |
318 | 625-630 | Species | denotes | human | Tax:9606 |
319 | 708-713 | Species | denotes | human | Tax:9606 |
320 | 43-50 | Chemical | denotes | aspirin | MESH:D001241 |
321 | 54-66 | Chemical | denotes | atorvastatin | MESH:D000069059 |
322 | 79-87 | Chemical | denotes | omega-3s | MESH:D015525 |
323 | 89-92 | Chemical | denotes | DPA | MESH:C026219 |
324 | 97-114 | Chemical | denotes | clupanodonic acid | MESH:C026219 |
325 | 116-122 | Chemical | denotes | DPAn-3 | |
326 | 151-158 | Chemical | denotes | Aspirin | MESH:D001241 |
327 | 163-175 | Chemical | denotes | atorvastatin | MESH:D000069059 |
328 | 228-241 | Chemical | denotes | hydroperoxide | MESH:D006861 |
329 | 714-722 | Disease | denotes | infected | MESH:D007239 |
330 | 435-439 | CellLine | denotes | RvT1 | CVCL:1045 |
331 | 471-475 | CellLine | denotes | RvT2 | CVCL:1045 |
332 | 506-510 | CellLine | denotes | RvT3 | CVCL:1045 |
333 | 564-568 | CellLine | denotes | RvT4 | CVCL:1045 |
334 | 792-796 | CellLine | denotes | RvT1 | CVCL:1045 |
335 | 798-802 | CellLine | denotes | RvT2 | CVCL:1045 |
336 | 823-827 | CellLine | denotes | RvT2 | CVCL:1045 |
337 | 833-837 | CellLine | denotes | RvT4 | CVCL:1045 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T87 | 0-150 | Sentence | denotes | In human platelets, COX-2 pre-treated with aspirin or atorvastatin metabolizes omega-3s, DPA and clupanodonic acid (DPAn-3), to 13S-hydroperoxy forms. |
T88 | 151-257 | Sentence | denotes | Aspirin and atorvastatin change the activity of COX-2 from cyclooxygenase to hydroperoxide-forming enzyme. |
T89 | 258-434 | Sentence | denotes | The intermediates formed are transported to the nearby human neutrophils and perhaps by the activity of the ALOX5 enzyme they are metabolized into four polyhydroxy metabolites: |
T90 | 435-594 | Sentence | denotes | RvT1 (7,13R, 20-trihydroxy-DPAn-3); RvT2 (7, 8,13R-trihydroxy-DPAn-3); RvT3 (7,12,13R-trihydroxy-8Z, 10E, 14E, 16Z, 19Z-DPAn-3); RvT4 (7,13R-dihydroxy-DPAn-3). |
T91 | 595-744 | Sentence | denotes | These four RvTs are formed by human neutrophils and vascular endothelial cells and are also found in rodents and human infected tissues (Dalli et al. |
T92 | 745-758 | Sentence | denotes | 2013a, 2015). |
T93 | 759-895 | Sentence | denotes | Recently, the total synthesis of RvT1, RvT2, and its 13R-epimer RvT2, and RvT4 were successfully achieved (Rodriguez and Spur 2020a, b). |
T94 | 896-1011 | Sentence | denotes | Therefore, it is expected that there will be many physiological and pharmacological research on RvTs in the future. |